"Serine Proteases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Peptide hydrolases that contain at the active site a SERINE residue involved in catalysis.
| Descriptor ID |
D057057
|
| MeSH Number(s) |
D08.811.277.656.959
|
| Concept/Terms |
Serine Proteases- Serine Proteases
- Proteases, Serine
- Serine Proteinases
- Proteinases, Serine
- Serine Proteinase
- Proteinase, Serine
- Serine Protease
- Protease, Serine
- Serine Protein Hydrolases
- Protein Hydrolases, Serine
|
Below are MeSH descriptors whose meaning is more general than "Serine Proteases".
Below are MeSH descriptors whose meaning is more specific than "Serine Proteases".
This graph shows the total number of publications written about "Serine Proteases" by people in this website by year, and whether "Serine Proteases" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 1 | 1 |
| 2012 | 1 | 0 | 1 |
| 2016 | 0 | 1 | 1 |
| 2017 | 0 | 1 | 1 |
| 2019 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Serine Proteases" by people in Profiles.
-
Intracerebroventricular Cerliponase Alfa for Neuronal Ceroid Lipofuscinosis Type 2 Disease: Clinical Practice Considerations From US Clinics. Pediatr Neurol. 2020 09; 110:64-70.
-
Upregulation of tripeptidyl-peptidase 1 by 3-hydroxy-(2,2)-dimethyl butyrate, a brain endogenous ligand of PPARa: Implications for late-infantile Batten disease therapy. Neurobiol Dis. 2019 07; 127:362-373.
-
Gemfibrozil, food and drug administration-approved lipid-lowering drug, increases longevity in mouse model of late infantile neuronal ceroid lipofuscinosis. J Neurochem. 2017 05; 141(3):423-435.
-
Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With?Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial. Gastroenterology. 2016 11; 151(5):893-901.e1.
-
Gemfibrozil and fenofibrate, Food and Drug Administration-approved lipid-lowering drugs, up-regulate tripeptidyl-peptidase 1 in brain cells via peroxisome proliferator-activated receptor a: implications for late infantile Batten disease therapy. J Biol Chem. 2012 Nov 09; 287(46):38922-35.
-
Gene therapy for late infantile neuronal ceroid lipofuscinosis: neurosurgical considerations. J Neurosurg Pediatr. 2010 Aug; 6(2):115-22.
-
Prenatal testing for late infantile neuronal ceroid lipofuscinosis. Ann Neurol. 2000 Feb; 47(2):254-7.